{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-072157","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2022-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.229179+00:00","generated_at":"2026-06-25T00:52:03.257109+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"VYNE completes Phase 2a enrollment for FMX114; extends In4Derm Oral BETi option to Feb 2023","bullets":["Enrollment completed in Phase 2a trial of FMX114 for mild-to-moderate atopic dermatitis; top-line results expected in 6-8 weeks.","Option term for Oral BETi Compounds extended to Feb 28, 2023; VYNE to pay In4Derm £300,000 by June 30, 2022.","Upon discovery of two Oral BETi Compounds with specified molecular profile, VYNE to pay In4Derm additional £850,000.","Previous Phase 1b segment showed statistically significant reduction in ADSI score and pruritus with FMX114 vs vehicle."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-072157","json":"https://secwatch.observer/filing/0001104659-22-072157.json","markdown":"https://secwatch.observer/filing/0001104659-22-072157.md","text":"https://secwatch.observer/filing/0001104659-22-072157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922072157/0001104659-22-072157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922072157/tm2218445d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T00:52:03.257109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}